A Parallel-Group, Randomized, Double-Blind, Multi-Center Dose Response Study To Evaluate The Efficacy And Safety Of PF-00885706, A 5-HT4 Receptor Partial Agonist, As Add-On Therapy To Esomeprazole For The Relief Of Symptoms In Subjects With Gastro-Esophageal Reflux Disease (GERD) Who Have A Poor Response To Proton Pump Inhibitor (PPI) Treatment.

Trial Profile

A Parallel-Group, Randomized, Double-Blind, Multi-Center Dose Response Study To Evaluate The Efficacy And Safety Of PF-00885706, A 5-HT4 Receptor Partial Agonist, As Add-On Therapy To Esomeprazole For The Relief Of Symptoms In Subjects With Gastro-Esophageal Reflux Disease (GERD) Who Have A Poor Response To Proton Pump Inhibitor (PPI) Treatment.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs PF 885706 (Primary)
  • Indications Gastro-oesophageal reflux
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 12 Feb 2009 Actual patient numbers (81) added as reported by ClinicalTrials.gov.
    • 12 Feb 2009 Planned end date changed from 1 Apr 2009 to 1 Oct 2008 as reported by ClinicalTrials.gov.
    • 12 Feb 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top